P/1Receipt of ethical clearance for trial from US Auth & listed...

P/1
Receipt of ethical clearance for trial from US Auth & listed on WHO & NIH clinical trial registers.
Grant is paying for trial a plus a no cost win for Stirling Pharma on this one.
Given previous trial success in Ukraine etc if all ok, which is more or less certain & if the World Health Organization pick this up for the treatment of patients its worth hundreds of millions per year to STI.
Results of trial at around end of year

P/2
Were told this month sales will begin in Australia and US Launch is beginning on a large scale for healthcare products. Manufacturing is beginning in new drug plant in Canada. This month with reporting we should see where were going. Its now or never. The blockbusters below are the company makers where if successful holders will make their money - they are in process but going to take a little time

(A) The Drug Inhalation Technology Platform is a masterful product but it will by the time US FDA approval is given it will be around April next year. It is seeking US approval for its patented Inhalation Drug Delivery Devices before embarking on large scale commercial production. A Section 510k is the requisite FDA approval required by all companies seeking to market any new medical device in the USA.

(B) Immunoxel. The more medical journal reports I read about Immunoxel/Dzherelo in medical journals the more I realise what world wide benefits and sales in the treatment of HIV and for all strains of TB, including Extremely Drug Resistant (XDR) TB and HIV co-infection. There is an application in process awaiting FDA approval for mid year. With the FDA if any medical initiative is truly innovative, and has life saving potential, FDA will deem it "Fast Track" and the approval process can take as little as 6 months. There is also a current trial taking place. It has been approved in South Africa already.
(C) Fat converter. Stirling owns the Intellectual Property and patent rights to ST-810 the world's only single enantiomer beta agonist, R-Salbutamol, for use in human obesity. A product that in animals converts energy from fat production into increased muscle mass. A Canadian trial is in progress.,
The potential market for the Company's human obesity drug candidate, subject to future regulatory approval, is valued well in excess of US$30 billion with the potential target market being over 65% of the western world population.
Patience is required for the processes I guess, and one hit with any of these is big time.
Peter Boonen is rolling the dices here, he has everything in place; products , manufacturing plant, top shelf personnel a workable plan with only one requirement now, the generation of cash.(which has started)

These are two posts from another forum that I thought do a good job of summing up where we sit today.(thanks posters)

The down side of todays 1cps is far outweighed by the potential to make a million.
Cheers P